Search Login Register
TNFR-Fc fusion protein
(etanercept)
Summary
1738
relevant articles (303 outcomes,
349 trials/studies)
found for this Drug
Description:
reduces tumor necrosis factor activity, as well as cytokine, chemokine, and stress hormone release; used to treat SPONDYLITIS, ANKYLOSING;
Also Known As:
etanercept; Enbrel; Immunex brand of etanercept; TNF receptor type II-IgG fusion protein; TNR 001 Show All >>
Key Diseases for which TNFR-Fc fusion protein is
Relevant
-
Rheumatoid Arthritis
:
75 outcomes 83 studies in 492 results
-
Psoriasis (Pustulosis Palmaris et Plantaris)
:
67 outcomes 68 studies in 303 results
-
Psoriatic Arthritis
:
28 outcomes 31 studies in 170 results
-
Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
:
28 outcomes 19 studies in 112 results
-
Ankylosing Spondylitis
:
20 outcomes 26 studies in 119 results
Show All >>
Drugs Related to TNFR-Fc fusion protein
-
infliximab (Remicade)
-
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
-
TNFR-Fc fusion protein (etanercept)
-
Methotrexate (Mexate)
-
adalimumab (Humira)
-
Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)
-
efalizumab
-
alefacept (Amevive)
-
Antirheumatic Agents (DMARD)
-
Interleukin 1 Receptor Antagonist Protein (Anakinra)
Show All >>
Therapies Related to TNFR-Fc fusion protein
-
Aftercare (After-Treatment)
-
Biological Therapy
-
Injections
-
Transplants (Transplant)
-
Laminectomy
Show All >>
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2009 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.